Self-Administered Med Shows Promise in Myasthenia Gravis

Published Date: 29 Apr 2026

Weekly subcutaneous gefurulimab delivered early is linked to lasting symptom improvement in patients with generalized myasthenia gravis in phase 3 PREVAIL trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reducing social media to an hour a day boosts young people's self-image.

2.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

3.

The pandemic had little impact on mental health symptoms.

4.

FDA Approves New Bladder Cancer First-Line Standard of Care.

5.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot